Science Sun Pharm(300485)2025-01-24 08:00Financial Performance Forecast - The company expects a net loss for 2024 between 105.09 million and 85.99 million RMB, compared to a profit of 122.16 million RMB in the same period last year, representing a decline of approximately 186.03% to 170.39%[4] - The total profit is projected to decrease significantly, primarily due to a reduction in fair value changes of financial assets and investment income from joint ventures, estimated at around -110 million RMB, a decline of about 170%[7] - The net profit attributable to shareholders is expected to be a loss between 88.76 million and 59.17 million RMB, compared to a profit of 102.92 million RMB last year[4] - Non-recurring losses are estimated to impact net profit by approximately -90 million RMB, mainly from fair value changes and investment income from trading financial assets[7] Revenue and Cost Management - The company's operating revenue is projected to be between 395.85 million and 437.52 million RMB, down from 476.57 million RMB in the previous year[4] - The company anticipates a growth in net profit after deducting non-recurring gains and losses, attributed to improved internal management and cost control, with reductions in selling and administrative expenses compared to the previous year[7] Audit and Reporting - The financial data presented is preliminary and has not been audited, with detailed figures to be disclosed in the 2024 annual report[8] - The company has communicated with its auditing firm regarding the performance forecast, and there are no discrepancies reported[6] - The performance forecast period is from January 1, 2024, to December 31, 2024[3] Investor Advisory - Investors are advised to make cautious decisions and be aware of investment risks due to the preliminary nature of the financial data[8]